Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia. - Wikidata - wikimedia - TriplyDB

Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia.

Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia.

http://www.wikidata.org/entity/Q37161899

about

Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance.Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.Clinical Weighting of Drug-Drug Interactions in Hospitalized Elderly.Population pharmacokinetics of kahalalide F in advanced cancer patients.Cancer therapeutics revisited; novel drugs targeting cell signalling pathways, genome wide association studies and other trials and tribulations.Mathematical modeling of efficacy and safety for anticancer drugs clinical development.

P2860

Q26766318-D29BA9D4-EF89-4E6A-B558-21C1E84B87F2 Q35979543-955CABF9-AD5B-48E4-979B-6AE5ABA049E2 Q35979551-CE77A6F0-2D98-423E-9A82-202060AC7D3D Q36924714-BF5604FC-D96C-432F-B57F-2DC31877472C Q38165041-8D4FC127-622F-45E0-8D7A-F97E4B0270ED Q40126912-9409CEF8-6C1E-4DC5-9458-89288467D746 Q40472063-C23C3BF1-14E8-49A5-940A-2C4BDACBF99F Q40816791-986D2885-1C2A-450E-A0D7-B04F2D95D32C Q42091213-077016B4-D411-4B6E-B116-A9D41088FC1D Q47663303-60A03DD6-22CF-408D-9B21-6DCBBEC651E0

P2860

Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia.

http://www.wikidata.org/entity/Q37161899

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Population pharmacokinetic-pha ...... silate-associated neutropenia.

@en

Population pharmacokinetic-pha ...... silate-associated neutropenia.

@nl

type

label

Population pharmacokinetic-pha ...... silate-associated neutropenia.

@en

Population pharmacokinetic-pha ...... silate-associated neutropenia.

@nl

prefLabel

Population pharmacokinetic-pha ...... silate-associated neutropenia.

@en

Population pharmacokinetic-pha ...... silate-associated neutropenia.

@nl

P1433

Q37161899-DBF8CBD3-C5A7-4EA5-8744-C6E0DBFEBCD0

P1476

Q37161899-E319CC32-76D0-449B-AD3E-B30530E06E7B

P2093

Q37161899-1B4DD6D3-6F2F-4D1E-9690-00641D8CD61F

Q37161899-2E7863D1-DFA3-4524-A233-4FDD20D99CE6

Q37161899-8C4EF435-1804-4C50-B7E3-64BAD670D79B

Q37161899-AA78321F-53DC-4F30-987D-B6641C5883B1

Q37161899-CE4D51D8-343C-4219-AEA7-7E932E1E3B52

Q37161899-FB86915C-6EC7-4635-AC5B-260B6DB9651E

P2860

Q37161899-0091F3F2-A731-488A-A27A-34134344F78A

Q37161899-10A2C84B-E9FB-4DED-81EB-14CF78EACEE1

Q37161899-115A60EC-B34D-4F9A-A808-22601911AD5F

Q37161899-13374455-B3E0-49CA-B44E-088C32CE5B50

Q37161899-3C404CD4-68A5-4F64-BE74-FFDF9613A478

Q37161899-499D05E1-250F-496D-8F3D-82F926D0E4FC

Q37161899-5A724834-B10E-4640-93D6-A23C756892F2

Q37161899-73CD018C-17AC-484C-AF13-1A28EBCDAE0C

Q37161899-79B8D73C-A6B0-4FC8-95C1-38A4CC12724B

Q37161899-9005DD12-BCDB-49EE-8FD1-E2B5B63ED1E2

P304

Q37161899-534AD4B7-768E-422C-A9E4-FA741462746F

P31

Q37161899-3792DEBA-4E04-4009-A9F6-54232C5FF4C1

P356

Q37161899-2B37BDC8-1C4C-4E1A-91CE-912D1EB8233E

P407

Q37161899-E336B009-A045-4CBD-83AC-212CECDBC656

P433

Q37161899-5B504457-437D-44D5-A9B6-80C8F4855C75

P478

Q37161899-EDF834DB-D77B-486C-AB1A-376EA5045264

P577

Q37161899-8B90314C-75E0-48B1-AEBD-5C31119CA80B

P5875

Q37161899-3BFC1325-B40E-4B78-81BE-EA1FA69EE7E6

P698

Q37161899-98004F6C-7E1F-4CA3-981C-8CC9478705FF

P932

Q37161899-B6B44F7B-F9D4-42B1-9475-298D9A6986A2

P356

P1433

British Journal of Clinical Pharmacology

P1476

Population pharmacokinetic-pha ...... silate-associated neutropenia.

@en

P2093

Alwin D R Huitema

http://www.w3.org/2001/XMLSchema#string

Anubha Gupta

http://www.w3.org/2001/XMLSchema#string

J G Coen van Hasselt

http://www.w3.org/2001/XMLSchema#string

Jan H M Schellens

http://www.w3.org/2001/XMLSchema#string

Jos H Beijnen

http://www.w3.org/2001/XMLSchema#string

Ziad Hussein

http://www.w3.org/2001/XMLSchema#string

P2860

Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression.

Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity.

Overview of resistance to systemic therapy in patients with breast cancer.

Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies.

Eribulin mesylate in patients with refractory cancers: a Phase I study.

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.

A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.

A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer.

Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM.

P304

412-424

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.12143

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236249893

http://www.w3.org/2001/XMLSchema#string

P698

23601153

http://www.w3.org/2001/XMLSchema#string

P932

3769668

http://www.w3.org/2001/XMLSchema#string